

Consolidated Development Pipeline by Phase



PHASE 3 (7 NMEs + 23 LCMs)

FILED (3 NME + 17 LCMs)

GASTROINTESTINAL AND INFLAMMATION

fazirsiran ★ AATD Liver Disease	ENTYVIO ® Pediatric UC	ENTYVIO ® GvHD Prophylaxis	ALOFISEL ® Perianal Fistulas in CD (US)	maralixibat ★ ALGS (JP)
ENTYVIO ® SC CD (US)	ENTYVIO ® Pediatric CD	ALOFISEL ® Pediatric perianal Fistulas in CD	maralixibat ★ PFIC (JP)	

ENTYVIO ® SC UC (US)	ENTYVIO ® SC UC (JP)
VOCINTI ® <i>H. Pylori</i> (CN)	ENTYVIO ® SC CD (JP)

NEUROSCIENCE

soticlestat ★ DS	soticlestat ★ LGS	pabinafusp alfa ★ Hunter Syndrome
----------------------------	-----------------------------	---

ONCOLOGY + Cell Therapy

EXKIVITY ® 1L NSCLC EGFR exon 20	fruquintinib mCRC (EU, JP)	ICLUSIG ® 1L Ph+ ALL (US)
NINLARO ® Maint. ND MM post-SCT (US, EU)	relugolix Prostate cancer (JP, CN)	CABOMETYX ® mCRPC combo w/atezolizumab (JP)

fruquintinib mCRC (US)	ADCETRIS ® R/R CTCL (JP)
ADCETRIS ® FL HL Stage III (EU)	

RARE GENETICS AND HEMATOLOGY

TAK-755 ★ cTTP (EU, JP, CN)	LIVTENCITY ® Post-transplant CMV infection (JP)	OBIZUR ® Recomb antihemophilic factor porcine (JP)
VONVENDI ® vWD Adult Prophylaxis (CN)	VONVENDI ® vWD Pediatric On-demand & Surgery	ADYNOVATE ® recombinant Factor VIII Pediatric Hema (EU)

TAK-755 ★ cTTP (US) ¹	VONVENDI ® vWD On-demand & Surgery (CN)	VONVENDI ® vWD Adult Prophylaxis (EU)
TAKHZYRO ® Pediatric HAE (US, EU) ²	OBIZUR ® Recomb antihemophilic factor porcine (CN)	

PLASMA-DERIVED THERAPIES

HYQVIA ® CIDP, MMN (JP)	HYQVIA ® PID (JP)	Prothromplex DOAC Reversal (US)
TAK-880 IgG – Low IgA (EU)	Glovenin-I ★ Autoimmune Encephalitis (JP)	

HYQVIA ® HyHub AVA Device (US)	HYQVIA ® CIDP (US, EU)	CUVITRU ® PID, SID (JP)	TAK-880 IgG – Low IgA (US)
HYQVIA ® Pediatric PID (US)	CEPROTIN ® Long-term prophylaxis SCPCD (EU)	CEPROTIN ® SCPCD (JP)	

VACCINES

Nuvaxovid ® COVID-19 Vaccine Booster (JP)	QDENG A ® Dengue Vaccine Booster
---	--

QDENG A ® Dengue Vaccine (EU + endemic countries)	QDENG A ® Dengue Vaccine (US)
---	---

1. Filing on-track

2. TAKHZYRO pediatric HAE approved in the US, filed in the EU

★ Orphan Drug Designation potential (in any region / indication for a given asset)

APPROVED

NME

LCM

All timelines are approximate estimates as of May 11, 2023, are subject to change and are subject to clinical and regulatory success. Table is not comprehensive. For full glossary of abbreviations please refer to appendix.

Consolidated Development Pipeline by Phase



	PHASE 1 (15 NMEs + 1 LCM)					PHASE 2 (17 NMEs + 1 LCM)				
GASTROINTESTINAL AND INFLAMMATION	TAK-105 Nausea & vomiting	TAK-647 NASH ¹				TAK-279 Psoriasis	TAK-101 Celiac Disease	TAK-951 Nausea & vomiting		
						TAK-279 Psoriatic Arthritis	TAK-227 Celiac Disease	zamaglutinase TAK-062 Celiac Disease		
NEUROSCIENCE	danavorexton TAK-925 Postanesthesia recovery	TAK-920 Alzheimer's Disease				TAK-861 NT1	TAK-071 Parkinson's Disease	TAK-041 Anhedonia in MDD	TAK-653 Inadequate resp. in MDD	
						TAK-861 NT2	TAK-341 MSA	TAK-594 Frontotemporal dementia	TAK-611 MLD (intrathecal)	
ONCOLOGY + Cell Therapy	TAK-102 Solid tumors	TAK-103 Solid tumors	TAK-186 EGFR Solid Tumor ²	TAK-940 CD19+ hematologic malignancies	modakafusp alfa Solid tumors	modakafusp alfa R/R MM	subasumstat Multiple cancers	TAK-007 CD19+ hematologic malignancies		
	TAK-500 Solid tumors	TAK-676 Solid tumors	TAK-280 B7-H3 Solid Tumor ²	ICLUSIG [®] Pediatric Ph+ ALL						
RARE GENETICS AND HEMATOLOGY	TAK-755 SCD	mezagitamab IgAN				mezagitamab MG	mezagitamab ITP	TAK-755 iTTP		
PLASMA-DERIVED THERAPIES						TAK-881 Immunodeficiencies				
VACCINES	TAK-426 Zika Vaccine									

- 1. Study actively recruiting
- 2. Currently in phase 1 of a phase 1/2 trial

★ Orphan Drug Designation potential (in any region / indication for a given asset)

NME

LCM

All timelines are approximate estimates as of May 11, 2023, are subject to change and are subject to clinical and regulatory success. Table is not comprehensive. For full glossary of abbreviations please refer to appendix.

Glossary of Abbreviations



Regional Abbreviations:

CN: China; EU: Europe; JP: Japan; US: United States of America

AAD	American Academy of Dermatology
AATD	α1-antitrypsin deficiency
AATD LD	α1-antitrypsin deficiency associated liver disease
ADAMTS13	a disintegrin-like and metalloproteinase with a thrombospondin type 1 motifs 13
ADHD	attention deficit hyperactivity disorder
ALGS	Alagille syndrome
ALK	anaplastic lymphoma kinase
ALL	acute lymphocytic leukemia
AVA	Advanced Vial Access
BLA	biologics license application
BMA	bradykinin mediated angioedema
BTD	breakthrough therapy designation
CAR NK	chimeric antigen receptor natural killer cell
CD	Crohn's disease
CHMP	Committee for Medicinal Products for Human Use
CIDP	chronic inflammatory demyelinating polyradiculoneuropathy
CML	chronic myeloid leukemia
CMV	cytomegalovirus
CPF	complex perianal fistulas
CRC	colorectal cancer
CRL	complete response letter
CRPC	castrate-resistant prostate cancer
CTCL	cutaneous T-cell lymphoma
cTTP	congenital thrombotic thrombocytopenic purpura
DOAC	direct oral anti-coagulation
DS	Dravet syndrome
EGFR	epidermal growth factor receptor

EMA	European Medicines Agency
EU-M4all	EU-Medicines for all
FDA	U.S. Food & Drug Administration
FL	front line
FSI	first subject in
FY	fiscal year
GI	gastrointestinal
GvHD	graft versus host disease
H2H	head-to-head
HAE	hereditary angioedema
HemA	hemophilia A
HL	Hodgkin lymphoma
HSCT	hematopoietic stem cell transplant
IARS	International Anesthesia Research Society
IBD	inflammatory bowel disease
IgA	immunoglobulin A
IgAN	immunoglobulin A nephropathy
IgG	immunoglobulin G
IND	investigational new drug
ITP	Immune thrombocytopenic purpura
iTTP	immune thrombotic thrombocytopenic purpura
JAK	Janus kinase
IV	intravenous
iPSC	induced pluripotent stem cells
LCM	lifecycle management
LD	liver disease
LGS	Lennox-Gastaut syndrome
mCRC	metastatic colorectal cancer
mCRPC	metastatic castrate-resistant prostate cancer
MDD	major depressive disorder

MG	myasthenia gravis
MLD	metachromatic leukodystrophy
MM	multiple myeloma
MMN	multifocal motor neuropathy
mNSCLC	metastatic non-small cell lung cancer
MSA	multiple system atrophy
MSS	microsatellite stable
NASH	non-alcoholic steatohepatitis
ND	newly diagnosed
NDA	new drug application
NEJM	New England Journal of Medicine
NK	natural killer
NME	new molecular entity
NMPA	(China's) National Medical Products Administration
NSCLC	non-small cell lung cancer
NT1 or 2	narcolepsy type 1 or 2
ORR	overall response rate
PASI	psoriasis area and severity index
PCD	protein C deficiency
PEX	plasma exchange
PFIC	progressive familial intrahepatic cholestasis
Ph+ ALL	Philadelphia chromosome-positive acute lymphoblastic leukemia
PID	primary immunodeficiency
PK	pharmacokinetics
PMDA	Japan's Pharmaceuticals and Medical Devices Agency
POC	proof of concept

POGD	post-operative gastrointestinal dysfunction
PRIME	Priority medicines scheme by EMA
PTH	parathyroid hormone
QD	quaque die, every day
R/R	relapsed/refractory
RTU	ready to use
SC	subcutaneous formulation
SCD	sickle cell disease
SCPCD	severe congenital protein C deficiency
SCT	stem cell transplant
SID	secondary immunodeficiency
SLE	systemic lupus erythematosus
SOC	standard of care
STING	stimulator of interferon genes
SUMO	small ubiquitin-related modifier
TCE	T-cell engager
TEAE	treatment emergent adverse event
TKI	tyrosine kinase inhibitor
TREM2	triggering receptor expressed on myeloid cells 2
TTP	thrombotic thrombocytopenic purpura
TYK2	tyrosine kinase 2
UC	ulcerative colitis
VEGFR	vascular endothelial growth factor receptors
vWD	von Willebrand disease
vWF	von Willebrand factor
WW	Worldwide